PI2620
Brief description of study
To investigate the sensitivity, specificity, and validity of the tau PET tracer [18F] PI-2620 for measuring toxic tau accumulation in the brain based on how the intensity and anatomical distribution of its uptake differs between cognitively normal adults, amyloid-positive individuals with suspected non-amnestic Alzheimers disease (naAD), and amyloid-negative individuals with suspected frontotemporal lobar degeneration (FTLD). To investigate differences between normal cognition, naAD, likely FTLD-tau, and likely FTLD-TDP patients in the anatomical distribution of tau uptake, as measured by [18F]PI-2620, demonstrating that a) [18F]PI-2620 uptake is higher in AD and FTLD tauopathies than in TDP-43 disease and cognitively normal seniors. To test associations between [18F]PI-2620 tau PET imaging measures and patients cognitive, motor, and functional impairment at baseline and approximately one year after the PET study visit.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
